Corrigendum to “Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials” [Urol Sci (2015) 41–48]

• Hann-Chorng Kuo,
• Ho-Hsiung Lin,
• Hong-Jeng Yu,
• Chen-Li Cheng,
• Man-Jung Hung,
• Alex Tong-Long Lin

Affiliations

Hann-Chorng Kuo

Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan

Ho-Hsiung Lin

Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan

Hong-Jeng Yu

Department of Urology, National Taiwan University Hospital, Taipei, Taiwan

Chen-Li Cheng

Department of Urology, Taichung Veterans General Hospital, Taichung, Taiwan

Man-Jung Hung

Department of Obstetrics and Gynecology, Taichung Veterans General Hospital, Taichung, Taiwan

Alex Tong-Long Lin

Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan